- Trial court was found to allowed improper scientific evidence
- J&J is facing a wave of talc-cancer trials early next year
The
The ruling comes as J&J is gearing up to face a
J&J shares were largely unchanged in late morning trading, down about 0.4% to $154.72
The jury in the case
The trials are in the wake of a bankruptcy judge’s decision in July to throw out the Chapter 11 filing of a J&J unit that was designed to propel an
“This marks the third time in three years that an appellate court has overturned outsized verdicts that asbestos lawyers secured by confusing and misleading juries with unscientific opinions touting baseless liability theories,” Erik Haas, a J&J vice president, said Tuesday in an emailed statement.
The New Brunswick, New Jersey-based company pulled its talc-based powders off the market in the US and Canada in 2020, citing slipping sales, and eventually replaced them with a cornstarch-based version. J&J has vowed to withdraw all its talc-based baby powders worldwide by the end of this year.
The appellate case is Barden vs. Brenntag North America, No A-0047-20, Superior Court of New Jersey, Appellate Division.
To contact the reporter on this story:
To contact the editors responsible for this story:
Elizabeth Wasserman
© 2023 Bloomberg L.P. All rights reserved. Used with permission.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.